Adecatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Adecatumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target EpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6552H10080N1740O2052S46
Molar mass 147.5 kg/mol
 NYesY (what is this?)  (verify)

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.[1]

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate[2] and breast cancers.[3] Phase II results were published in 2010.[4]

References[edit]

  1. ^ http://adisinsight.springer.com/drugs/800013072[full citation needed]
  2. ^ Oberneder, Ralf; Weckermann, Dorothea; Ebner, Beatrice; Quadt, Cornelia; Kirchinger, Petra; Raum, Tobias; Locher, Mathias; Prang, Nadja; Baeuerle, Patrick A.; Leo, Eugen (2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8. PMID 16930989. doi:10.1016/j.ejca.2006.05.029. 
  3. ^ Prang, N; Preithner, S; Brischwein, K; Göster, P; Wöppel, A; Müller, J; Steiger, C; Peters, M; Baeuerle, P A; Da Silva, A J (2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". British Journal of Cancer. 92 (2): 342–9. PMC 2361858Freely accessible. PMID 15655555. doi:10.1038/sj.bjc.6602310. 
  4. ^ Schmidt, M.; Scheulen, M. E.; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Ruttinger, D.; Schuler, M.; Reinhardt, C.; Awada, A. (2009). "An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer". Annals of Oncology. 21 (2): 275–82. PMID 19633042. doi:10.1093/annonc/mdp314.